Alleviant ALLAY-HF Study

Conditions

• Heart Failure

Eligibility Criteria

Sex

ALL

Age

40 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Alleviant ALV1 System — DEVICE
  Creation of interatrial shunt
• Sham-Control — OTHER
  Cardiac imaging

Study Details

Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

Key Dates

First listed

Jan 17, 2023

Start date

Jan 10, 2023

Status verified

Aug 2026

Primary completion

Dec 1, 2027

Completion

Dec 1, 2032

Study Design

Enrollment

700 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Arms

• Experimental: Treatment
  Subjects randomized to the treatment arm will undergo cardiac imaging, femoral vein access and receive the Alleviant ALV1 System device procedure.
• Sham Comparator: Control
  Subjects randomized to the control arm will undergo cardiac imaging and sheath placement in femoral vein.

Primary Outcome Measure

Composite Primary Endpoint [ Time Frame: 12-month ]

Central Contacts

• Jennifer Olson
  +1 612 327 2741
  [email protected]

Locations (56)

Find similar trials in Phoenix, AZ

Related Studies

• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  Recruiting · Medtronic · Birmingham, Alabama
• Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
  Recruiting · UConn Health · Farmington, Connecticut
• Identification of Genomic Predictors of Adverse Events After Cardiac Surgery
  Recruiting · Brigham and Women's Hospital · Dallas, Texas
• Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
  Recruiting · Arunark Kolipaka · Columbus, Ohio